Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.670
-0.030 (-1.76%)
At close: Jun 3, 2026, 4:00 PM EDT
1.662
-0.008 (-0.50%)
After-hours: Jun 3, 2026, 4:55 PM EDT

Inhibikase Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
28727022581337
Market Cap Growth
58.73%19.76%2769.29%-38.01%-65.73%-46.68%
Enterprise Value
118.591.2127.88-4.92-10.17-3.52
Last Close Price
1.672.053.251.273.008.82
PS Ratio
---30.16102.6611.93
PB Ratio
1.731.562.380.720.600.96
P/TBV Ratio
1.191.170.810.700.600.70
EV/Sales Ratio
----18.90-82.40-1.14
EV/EBITDA Ratio
---0.250.560.24
EV/EBIT Ratio
---0.250.560.24
EV/FCF Ratio
---0.270.580.25
Debt / Equity Ratio
-000.040.010.01
Net Debt / Equity Ratio
-1.02-1.03-1.03-1.15-1.08-1.05
Net Debt / EBITDA Ratio
3.093.443.410.631.252.74
Net Debt / FCF Ratio
4.776.435.090.701.292.83
Asset Turnover
-000.010.000.11
Quick Ratio
29.8321.5426.133.856.2510.08
Current Ratio
30.1421.7026.374.136.5910.47
Return on Equity (ROE)
-29.93%-36.05%-52.00%-118.88%-60.74%-61.35%
Return on Assets (ROA)
-31.15%-37.15%-50.55%-101.87%-53.79%-51.58%
Return on Invested Capital (ROIC)
-2078.85%-2354.08%-5262.44%-2611.63%-3777.10%-1128.40%
Return on Capital Employed (ROCE)
-32.43%-38.82%-53.98%-124.36%-60.78%-60.92%
Buyback Yield / Dilution
-167.35%-314.60%-293.35%-42.74%-39.15%-121.72%
Total Shareholder Return
-167.35%-314.60%-293.35%-42.74%-39.15%-121.72%
SEC Filings: 10-K · 10-Q